Reading LUCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUCY free→Reading LUCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUCY free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been steady. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, LUCY trades below typical levels. Peer multiples imply a price about 31% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.86. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.86 LUCY trades at 1× p/s, below its 3× p/s peer median. Our $3.16 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 81% below a flat-multiple fair value, below our forecast of about 92%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.43 → $-0.37 (+14.0% / 30d). 1 raised, 0 cut, 1 covering analysts.
0 upgrades, 1 downgrade / 30d, 0 maintained. 50% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$179.
How much price usually moves either way.
On a bad day, this stock has moved -$821.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,569.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LUCY yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On January 7, 2026, Innovative Eyewear, Inc. (the “Company”) issued a press release announcing preliminary financial results and operational highlights for the 2025 fiscal year. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K. This information is intended to be furnished under Items 2.02 and 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LUCY INNOVATIVE EYEWEAR INC | Below typical Show detailsSector percentile: 30 of 100 | inexpensive | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 4, 2025, Konrad Dabrowski resigned as the Co-Chief Financial Officer of Innovative Eyewear, Inc. (the “Company”) and agreed to a change in title to Chief AI and Growth Officer of the Company. Oswald Gayle, who has served as the Company’s Co-Chief Financial Officer alongside Mr. Dabrowski, will now hold the title of Chief Financial Offic…
Other Events. On August 15,2025, Innovative Eyewear, Inc. (the “Company”) filed a prospectus supplement to increase the maximum number of shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., dated April 15, 2024. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Ellenoff Grossman & Schole LLP relating to the legality of the issuance and s…
Entry into a Material Definitive Agreement On June 20, 2025, Innovative Eyewear, Inc., a Florida corporation (the “Company”), entered into inducement letter agreements (the “Inducement Letter Agreements”) with certain holders (the “Holders”) of certain of its existing warrants to purchase an aggregate of 746,782 shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), which were originally issued to the Holders on April 14, 2025, having an original exercise pri…
The New Warrants, PA Warrants, Ordinary Course PA Warrants, New Warrant Shares, PA Warrant Shares and Ordinary Course PA Warrant Shares are being sold and issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. Such sec…